Pharmacokinetics of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum with and without efavirenz-based antiretroviral treatment: IMPAACT P1026s study
Observational analysis examines drug exposure during pregnancy and postpartum in women on antiretroviral treatment, suggesting implications for tuberculosis management.
Key Points
Lower exposure of rifampin in pregnant women on efavirenz treatment might affect tuberculosis treatment outcomes.
Rifampin levels were 42% and 35% lower during the third trimester compared to non-HIV individuals.
Assessments of the pharmacokinetics of four tuberculosis drugs were performed across various stages: pregnancy and postpartum.
This study highlights a potential clinical concern regarding proper tuberculosis dosage in pregnant women on antiretroviral therapy.